CourtneyDentonDiNardoMD

PubMed

• 1 citations
  Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
  Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Récher, Walter Fiedler, Kazuhito Yamamoto, Jianxiang W...> ;American Journal of Hematology. 2024 Apr 1
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
  Alex Bataller, Courtney D DiNardo, Alexandre Bazinet, Naval G Daver, Abhishek Maiti, Gautam Borthakur, Nicholas Short, Koji Sasaki, Elias J Jabbour, Ghayas C Issa, Nav...> ;American Journal of Hematology. 2024 Apr 1
• Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm,...
  Alexandre Bazinet, Hagop Kantarjian, Alex Bataller, Naveen Pemmaraju, Gautam Borthakur, Kelly Chien, Yesid Alvarado, Prithviraj Bose, Elias Jabbour, Musa Yilmaz, Court...> ;The Lancet. Haematology. 2024 Apr 1
• Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
  Alberto Risueño, Wendy L See, Iryna Bluemmert, Stéphane de Botton, Andre C Schuh, Pau Montesinos, Paresh Vyas, Anita Gandhi, Maroof Hasan, Courtney D DiNardo, Amir T F...> ;Leukemia Research. 2024 Mar 27
• Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
  Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza, Kelly Sharon Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasak...> ;Blood Advances. 2024 Mar 21
• Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.
  Pau Montesinos, Stéphane de Botton, Yue Zhu, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Amir T Fathi, Eytan M Stein, Amer M Zeidan, Thomas Prebet, Courtney D DiNardo> ;Blood Advances. 2024 Mar 20
• Author Correction: Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.
  Karl-Heinz Tomaszowski, Sunetra Roy, Carolina Guerrero, Poojan Shukla, Caezaan Keshvani, Yue Chen, Martina Ott, Xiaogang Wu, Jianhua Zhang, Courtney D DiNardo, Detlev ...> ;Nature Communications. 2024 Mar 12
• Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
  Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti...> ;The Lancet. Haematology. 2024 Apr 1
• Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
  Ziyi Li, Rashmi Kanagal-Shamanna, Guillermo Montalban-Bravo, Danielle Hammond, Sherry A Pierce, Kelly S Chien, Faustine Ong, Kunhwa Kim, Courtney D DiNardo, Koichi Tak...> ;Cancer Medicine. 2024 Mar 1
• Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia.
  Guillermo Montalban-Bravo, Juan Jose Rodriguez-Sevilla, David Michael Swanson, Rashmi Kanagal-Shamanna, Danielle Hammond, Kelly Chien, Koji Sasaki, Elias Jabbour, Cour...> ;Leukemia. 2024 Feb 28
• Hematologic malignancies in Li-Fraumeni syndrome: A case report.
  Bethany Bundrant, Yoheved Gerstein, Banu Arun, Courtney D DiNardo> ;American Journal of Medical Genetics. Part A. 2024 Feb 27
• BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
  Warren Fiskus, Jessica Piel, Michael P Collins, Murphy Hentemann, Branko Cuglievan, Christopher P Mill, Christine Birdwell, Kaberi Das, John A Davis, Hanxi Hou, Antrix...> ;Blood. 2024 Feb 16
• Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
  Dinh, A., Savoy, J., Rausch, C., Kontoyiannis, D., Takahashi, K., Issa, G., Kantarjian, H., DiNardo, C.> ;Cancer. 2024 Feb 10
• Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).
  Mill, C., Fiskus, W., DiNardo, C., Reville, P., Davis, J., Birdwell, C., Das, K., Hou, H., Takahashi, K., Flores, L., Ruan, X., Su, X., Loghavi, S., Khoury, J., Bhalla...> ;Blood Cancer Journal. 2024 Feb 5
• Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.
  Ravandi, F., Pierce, S., Sasaki, K., Kadia, T., DiNardo, C., Yilmaz, M., Short, N., Jabbour, E., Patel, K., Loghavi, S., Borthakur, G., Kantarjian, H.> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
  Pasvolsky, O., Saliba, R., Popat, U., Alousi, A., Mehta, R., Yeh, J., Al-Atrash, G., Adeel, M., Ramdial, J., Marin, D., Rondon, G., Kebriaei, P., Champlin, R., Daver, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2024 Feb 3
• Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
  Alexandre Bazinet, Sai Prasad Desikan, Ziyi Li, Juan Jose Rodriguez-Sevilla, Sangeetha Venugopal, Samuel Urrutia, Guillermo Montalban-Bravo, Koji Sasaki, Kelly S Chien...> ;Clinical Cancer Research. 2024 Apr 1
• Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory-Mutated AML.
  Short, N., Daver, N., Dinardo, C., Kadia, T., Nasr, L., Macaron, W., Yilmaz, M., Borthakur, G., Montalban-Bravo, G., Garcia-Manero, G., Issa, G., Chien, K., Jabbour, E...> ;Journal of Clinical Oncology. 2024 Jan 26
• 1 citations
  Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
  Bataller, A., Bazinet, A., DiNardo, C., Maiti, A., Borthakur, G., Daver, N., Short, N., Jabbour, E., Issa, G., Pemmaraju, N., Yilmaz, M., Montalban-Bravo, G., Takahash...> ;Blood Advances. 2024 Feb 27
• Toward an improved understanding of hypomethylating agent and venetoclax therapies.
  DiNardo, C.> ;American Journal of Hematology. 2024 Feb 1
• Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression.
  Birdwell, C., Fiskus, W., Kadia, T., Mill, C., Sasaki, K., Daver, N., DiNardo, C., Pemmaraju, N., Borthakur, G., Davis, J., Das, K., Sharma, S., Horrigan, S., Ruan, X....> ;Leukemia. 2024 Mar 1
• Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients.
  Jen, W., Rausch, C., Alvarado, Y., McCue, D., Ravandi, F., Sasaki, K., DiNardo, C., Kadia, T., Yilmaz, M., Borthakur, G., Kantarjian, H., McCue, D.> ;Leukemia & Lymphoma. 2024 Mar 1
• 2 citations
  Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
  Fadi G Haddad, Nicholas J Short, Jayastu Senapati, Nitin Jain, Koji Sasaki, Yesid Alvarado, Xuemei Wang, Lucia Masarova, Farhad Ravandi, Elias Jabbour, Jeffrey Jorgens...> ;Blood. 2024 Feb 1
• 1 citations
  Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.
  Danielle Hammond, Sanam Loghavi, Sa A Wang, Marina Y Konopleva, Tapan M Kadia, Naval G Daver, Maro Ohanian, Ghayas C Issa, Yesid Alvarado, Nicholas J Short, Koji Sasak...> ;Blood Cancer Journal. 2023 Sep 21
• 7 citations
  Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
  Alex Bataller, Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S Chien, Danielle Hammond, Guillermo Montalban-Bravo, Gautam Borthakur, Nicholas ...> ;American Journal of Hematology. 2023 Nov 1
• Join now to see all

Journal Articles

• Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia  
  Courtney D Dinardo, Brian A Jonas, Jacqueline S Garcia, Anthony Letai, Wan-Jen Hong, Keith W Pratz, The New England Journal of Medicine
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)  
  Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Marina Konopleva, Steven Kornblau, Hagop Kantarjian, Nitin Jain, Elias Jabbour, Courtney D DiNardo, Michael Andreeff, Nature
• Integrative Genomic Analysis of Adult Mixed Phenotype Acute Leukemia Delineates Lineage Associated Molecular Subtypes  
  Koichi Takahashi, Nitin Jain, Courtney D. DiNardo, Steven Kornblau, Carlos Bueso-Ramos, Marina Konopleva, Hagop Kantarjian, Nature
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Join now to see all

Abstracts/Posters

• High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosid...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in O...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Com...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ib/II Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly D...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clonal Dynamics and Clinical Implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML)
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remis...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Acceleration of AML Progression By Cigarette Smoke Exposure or Condensate Exposure and Associated DNA Methylation Alterations
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcomes of Therapy-Related Versus De Novo Acute Myeloid Leukemia with Normal Karyotype
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Targeting DHODH with AG-636 Induces Apoptosis and Differentiation and Inhibits Mitochondrial Function in AML, Translating into Anti-Tumor Efficacy in Vitro and in Vivo
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphob...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myelo...
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens
  Courtney D. DiNardo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Therapy of Acute Myeloid Leukemia: Adapting to Change 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML). 
  2019 ASCO Annual Meeting - 6/1/2019
• Results of a Phase 1, Dose-Escalation Study of FF-10501-01 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Hypomethylating Agent (HMA)-Resistant M... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Diverse Landscape of TET2 Variants in MDS and AML 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Pan-Myeloid Leukemia Analysis: Machine Learning-Based Approach to Predict Phenotype and Clinical Outcomes Using Mutation Data 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Evaluation of Romyelocel-L Myeloid Progenitor Cells to Decrease Infections in De Novo AML Patients Receiving High-Dose Ara-C-Based Induction Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Single-Cell Atlas of Driver Mutations in Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical Applications for Next Generation Sequencing 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Join now to see all